HAI-Floxuridine, or Liver-Tx, Combined With 2nd Line Chemotherapy Versus 2nd Line Chemotherapy Alone for Patients With Colorectal Liver Metastases and Heavy Tumour Burden. (EXCALIBUR1+2)
EXtended CriteriA Treatment for LIver Metastases With Heavy Tumour BURden 1 + 2
Sponsor: Oslo University Hospital
Listed as NCT04898504, this PHASE2 trial focuses on Chemotherapy Effect and Colorectal Cancer and remains ongoing. Sponsored by Oslo University Hospital, it has been updated 6 times since 2021, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Dec 2024 — Present [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Dec 2024 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Sep 2023 — Jul 2024 [monthly]
Recruiting PHASE2
-
Sep 2021 — Sep 2023 [monthly]
Recruiting PHASE2
▶ Show 1 earlier version
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Oslo University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .